Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Join this hour-long webinar exploring strategies to mitigate toxicities in Antibody-Drug Conjugates (ADCs) through innovative linker-payload design. Learn from Senior Scientist Matthew Giese as he delves into the challenges of ADC development, where despite FDA approvals, treatment-related adverse events remain a significant concern. Discover how less than 1% of administered cytotoxins reach intended tumor targets, and explore how PEG-based components in linker-payload design can enhance pharmacokinetic parameters, tolerability, and biodistribution. Gain insights into optimizing preclinical assays to reduce downstream development risks, understand various ADC processing mechanisms, and examine how different ADC elements influence tissue partitioning. Master the critical balance between efficacy and toxicity in ADC development while exploring practical use cases demonstrating improved performance through PEG-containing linker-payload designs.
